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Since the ﬁrst report on Brugada syndrome, various risk markers for the prediction of ventricular
ﬁbrillation (VF) in patients with Brugada syndrome have been reported. Multicenter trials reported
spontaneous type 1 electrocardiogram (ECG) and disease symptoms as prognostic predictors. VF
induction by programmed electrical stimulation is still controversial, and most of the studies have
failed to prove its signiﬁcance for the prediction of spontaneous VF episodes. In Japan, although most
multicenter studies have shown that patients with type 1 ECG were at high risk, it is difﬁcult to
determine the indication for implantation of an implantable cardioverter deﬁbrillator only based on the
ECG type. Recent studies have added new risk markers, such as inferolateral early repolarization,
fragmented QRS, and shorter effective refractory periods of the ventricle, in addition to type 1 ECG and
symptoms. Here, we review the clinical outcome and indices reported as reliable prognostic factors of
Brugada syndrome with a focus on the clinical and ECG markers for risk stratiﬁcation.
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Twenty years have passed since the ﬁrst report on Brugada
syndrome [1]. The interesting electrocardiogram (ECG) character-
istics of this syndrome have attracted the attention of many
physicians and researchers, and almost 2000 reports on Brugada
syndrome have been published. Symptomatic patients who have
had a previous episode of aborted cardiac arrest (ACA) and
syncope are at high risk for recurrent ventricular tachyarrhyth-
mias. Previous studies that evaluated the long-term prognosis of
Brugada syndrome patients have shown that a previous episode
of ACA and syncope are high-risk markers [1–5]. Some studies
have also shown various clinical risk factors for identifying high-
risk patients (Table 1). Most of the observations from which risk
factors for ventricular ﬁbrillation (VF) were identiﬁed were
carried out in patients who experienced cardiac arrest or VF,
and it is still not clear whether these risk factors can identifyTable 1
Risk markers reported in Brugada syndrome.
Clinical characteristics ECG markers
Male Repolarization abnormality
Syncope Spontaneous type 1 ECG
Family history of sudden death ST level (V2)
ST augmentation after exe
ST augmentation after me
QT prolongation, longer Tp
Inferolateral early repolari
Spontaneous alteration of
T wave alternans (macros
Negative T wave (V1)
Depolarization abnormality
PQ prolongation
Fragmented QRS
QRS widening
aVR sign
Arrhythmias
Atrial ﬁbrillation/SSS/AV b
Table 2
Long-term prognosis in Brugada syndrome.
Brugada
1998 [6]
Priori
2000
[82]
Atarashi
2001 [83]
Brugada
2002 [2]
Brugada
2003 [84]
Eckar
2005
Number of pts 63 60 105 334 547 212
Age (years) 38717 40715 45713 42716 41715 4576
Follow-up
(months)
34732 33738 36 33739 24732 4075
Male (%) 90 75 94 76 75 72
Symptoms (%)
Asymptomatic 35 50 64 57 77 58
Syncope 32 22 17 22 23 31
VF 33 28 19 21 0 11
Induced VF (%) 80 (37/
46)
67 (26/
39)
NA 52 (130/
252)
40 (163/
408)
50 (9
186)
VF event rate (%/yr)
Asymptomatic
pts
12 0 0.5 3.5 1.5 0.2
Pts with
syncope
18 4 8.6 8.8 7.0 1.8
Pts with VF 11 13.8 – 5.1
Predictors
ECG – – – Spont.
type
1 ECG
Spont.
type
1 ECG
Spont
type
1 ECG
Symptom – – – – Syncope ACA /
synco
EPS – – – Induced
VT/VF
Induced
VT/VF
–high-risk patients among those in whom VF has not been
documented.
Here, we review the clinical outcome and indices reported as
reliable prognostic factors of Brugada syndrome with a focus on
the clinical and ECG markers for risk stratiﬁcation.
1.1. Long-term prognosis of Brugada syndrome
Brugada et al. [6] published the ﬁrst report on the long-term
prognosis of patients with Brugada syndrome. They followed 63
patients (including 22 asymptomatic patients) for 34 months and
found a high incidence of cardiac events (30% during follow-up)
regardless of the presence or absence of symptoms. Subsequent
studies showed relatively lower incidences of VF events, espe-
cially in patients without documented VF, and recent studies have
shown that the event rates were 0.5–1% per year in asymptomatic
patients and 0.6–3.4% per year in patients with syncope [3–5].Additional examination
Signal-averaged electrogram
Late potential
rcise Antiarrhythmic drug test
al/full stomach/glucose Pilsicainide-induced TWA, VT
eak–Tend
zation Electrophysiological study
ST level/ECG types PES-induced VF
copic)
Mode of induction
ERPo200 ms
lock
dt
[85]
Takagi 2007 [67] Kamakura
2009 [5]
Probst [3]
(FINGER
registry)
Priori [4]
(PRELUDE
registry)
188 330 1029 308
53714 51719 45 (35 to 55) 47712
0 37716 49715 32 (14 to 54) 3678
95 95 72 80
52 63 64 79
26 20 30 21
22 17 6 0
3/ 78 (114/146) 59 (138/232) 41 (262/638) 41 (126/308)
0 0.5 0.5 1
1.9 0.6 1.9 3.6
9.8 10.2 7.7 -
. rJ (V2) Z90 ms
QRS (V6) Z90 ms
Inferolateral ER Spont. type
1 ECG
QRS
fragmentation
pe
– Family history of
SD o45 years
Syncope Syncope
– – – ERP o200 ms
T. Wada, H. Morita / Journal of Arrhythmia 29 (2013) 100–109102Patients with previously documented VF still had high event rates
(7.7–10.2% per year) in recent studies [2,3,5,7] (Table 2, Fig. 1).
These studies proved that the spontaneous appearance of type
1 ECG, syncope, and ACA were high-risk markers for VF events
during follow-up. Prospective studies carried out in the past
3 years added the existence of inferolateral early repolarization
(ER) and QRS fragmentation to the risk markers predicting VF
events [4,5]. The value of VF induction by programmed electrical
stimulation for risk stratiﬁcation in Brugada syndrome was
controversial [8–10]; however, meta-analyses of the results of
VF induction failed to prove the usefulness of induced VF for risk
stratiﬁcation [11,12].
On the basis of a meta-analysis involving 1545 patients performed
in 2006, it was concluded that a history of syncope or aborted sudden
cardiac death (SCD) (relative risk [RR], 5.51), spontaneous type 1 ECG
(RR, 4.65), and male gender (RR, 4.47) can predict the prognosis of
patients; however, family history of sudden death, sodium channel
gene (SCN5A) mutation, and programmed stimulation cannot predict
the subsequent occurrence of VF [11].2. Clinical characteristics and prognosis
2.1. Symptoms
A previous episode of ACA is a high-risk marker of VF recurrence
during follow-up (hazard ratio [HR], 11) [3]. Therefore, implantationFig. 1. Prognosis of Brugada syndrome according to symptoms. Asymptomatic
patients had good prognosis; however, the event rates increased in patients with
syncope and ventricular ﬁbrillation. Data from 250 patients (asymptomatic,
170 patients; syncope, 67 patients; aborted cardiac arrest, 17 patients).
Type 0 Type 1
ECG types of Bruga
V1
V2
V3
Fig. 2. ECG types of Brof an implantable cardioverter deﬁbrillator (ICD) should be recom-
mended for the secondary prevention of SCD [13]. It is also acceptable
to implant an ICD in patients with documented ventricular tachy-
cardia (VT) not resulting in aborted SCD.
An episode of syncope is a sensitive predictor of sudden cardiac
arrest in patients with Brugada syndrome (HR, 2.5–6.4) [3,4,7,14].
Recording of a spontaneous or a drug-induced type 1 ECG is
important for detecting high-risk patients among those who have
had syncope episodes [15]. Indeed, 20% of sudden death cases caused
by this syndrome had at least 1 syncope episode before the fatal
event [16]. However, not all syncope episodes occur from VF, and
syncope can also occur from bradyarrhythmias, neutrally mediated
syncope, and epileptic seizures [17,18]. An extracardiac cause of
syncope should be excluded at the time of diagnosis; however, it is
sometimes difﬁcult to prove that a patient’s symptoms have not
resulted from VF unless an ECG is recorded during the episode itself.
Then, it is important to evaluate the circumstances and the existence
of a prodrome at the onset of the syncope episode [19]. Recently, we
reported that syncope episodes with prodromes, especially symptoms
such as blurred vision (HR, 0.20), diaphoresis, and symptoms related
to urination, are less frequently associated with VF episodes and may
be associated with benign episodes. In contrast to these symptoms,
the absence of these prodromes and abnormal respiration at night
(HR, 2.39) are independently associated with VF episodes [20].
2.2. Family history of sudden death and SCN5A mutation
Although most of the European studies failed to prove an
association between family history of sudden death and VF events
[3,4,7,21], frequent sudden deaths in family members were
recognized [22]. A Japanese registry proved that a family history
of sudden death (o45 years) was an independent predictor of
subsequent VF events (HR, 3.28) [5].
In most series, there was no difference in arrhythmic events
according to the presence or absence of mutations of the cardiac
sodium channel gene (SCN5A) [3,11,14]. Some studies have shown
a signiﬁcantly higher rate of recurrent VF among patients carrying
SCN5A mutations [23] and loss-of-function mutations, compared
with patients without such mutations [24]. Mutations associated
with calcium and potassium channels and the b-subunit of the
sodium channel are rare [25], and the impact of these mutations
on prognosis is unclear.
2.3. Gender difference and children
It is well known that Brugada syndrome has a male predomi-
nance (80%) [26]. In an experimental model of Brugada syndrome,
male canines have been shown to frequently have the BrugadaType 2 Type 3
da syndrome
ugada syndrome.
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the development of this syndrome [28,29]. Men had greater rates of
spontaneous type 1 ECG, greater ST-segment elevation, and greater
inducibility of VF than women. Male gender was signiﬁcantly
related to cardiac events during follow-up (HR, 4.45) [11,21,30].
Spontaneous VF or sudden death usually occurs at middle age
[31], and Brugada-type ECG in children is very rare. The prevalence
of Brugada-type ECG in children has been reported to be 0.005–
0.0098% [32,33], and it increases up to puberty. Although its
incidence is low, children with Brugada syndrome can show severe
clinical forms [1,34]. Severe infant cases have also been reported
and are associated with conduction abnormality. Syncope episodes
in children are frequently precipitated by fever [34].3. Repolarization abnormality and prognosis
3.1. Type 1 ECG and prognosis
The diagnosis of Brugada syndrome requires the existence of
type 1 ECGs. Report of the Second Consensus conference stated
that type 1 ECG is only diagnostic of Brugada syndrome and is
deﬁned by a coved ST-segment elevation of Z2 mm (0.2 mV)
followed by a negative T wave (Fig. 2). The criteria for the
diagnosis of Brugada syndrome are the existence of type 1 ECG
in the presence or absence of a sodium channel blocker and VF/VF
(spontaneous or induced), symptoms (syncope or agonal respira-
tion), and family history of sudden death [13]. Type 1 ECG has
been identiﬁed as an independent predictor of ventricular
tachyarrhythmias in multivariate analyses of the largest cohorts
of patients [2,3,14,35]. The HR of spontaneous type 1 ECG was
reported [3] to be 1.8, and it increases when it is combined with
the patient’s symptom (syncope) (HR, 4.2–6.4) [7,14].
Type 1 ECG is usually prominent in lead V2 [36], especially at high
intercostal spaces (ICSs) [37,38]. If patients only have type 1 ECG at
leads V1 and V2 of the 2nd or 3rd ICS and do not show typical ECG in
standard lead locations, the prognosis of the patients is similar to that
of patients with a type 1 ECG in standard leads V1 and V2 [39]. This
observation indicates that detection of type 1 ECG is important
irrespective of the location of leads V1 and V2. Type 1 ECG at lead
V2 represents abnormal repolarization at the right ventricular out-
ﬂow tract (RVOT), and a variation in the relative location between the
RVOT and lead V2 will cause different appearances of typical
Brugada-type ECG at the 2nd to 4th ICSs [40].
Experimental observations have shown that VF occurs when
the morphology of the epicardial action potentials (APs) changes
functionally and results in prominent heterogeneity of APs within
the epicardium. These arrhythmogenic AP changes are accompa-
nied by ECG morphology changes from type 1 ECG to coved-type
ST elevation with shallowing of the negative T wave or without
negative T waves [41]. Take et al. deﬁned this type as ‘‘type
0 ECG’’ and found that it frequently appeared in association with
VF episodes (Fig. 2).
3.2. Non-type 1 ECGs
Patients with type 2 and 3 ECGs are thought to have a more
benign clinical course compared with patients with spontaneous
type 1 ECGs. In the Consensus reports, these ECG types were
deﬁned as saddleback-type ST segment (Z2 mm) with a positive
or biphasic T wave (type 2) and a saddleback or coved-type ST
segment of o1 mm (type 3) [13], and these types are considered
non-diagnostic ECG.
From the experimental model of Brugada syndrome, these ECG
types represent less arrhythmogenic abnormality of repolariza-
tion [42]. However, not all patients without spontaneous type1 ECG have good prognosis. Indeed, patients without spontaneous
type 1 ECG who have experienced ACA had a recurrence of VF
during follow-up [5]. Administration of a sodium channel blocker
is used to unmask type 1 ECG from non-type 1 ECGs, and it can
identify high-risk patients among those with non-type 1 ECGs.
The prognosis for patients with drug-induced type 1 ECG is worse
than that for patients without such ECG manifestations [43].
A recent study showed that the response to sodium channel
blocker can be predicted by measurement of the angle of the late
r0 wave (angle between the upstroke of the S wave and downslope
of the r0 wave) [44]. Patients with drug-induced type 1 ECG had a
blunter r0 wave than did patients without such ECGs, and the
cutoff value was 581 (Fig. 3).
3.3. Alternation in ST-T segment
T-wave alternans (TWA) represents an unstable repolarization
process and is often observed in patients with long QT syndrome.
Unstable repolarization promotes heterogeneity of APs and
initiates ventricular arrhythmia. A Brugada syndrome model
showed the instability of the epicardial AP in the RVOT that
resulted in macroscopic TWA and promoted ventricular arrhyth-
mias [42,45]. In patients with Brugada syndrome, macroscopic
TWA occurred as beat-by-beat alternans of the negative T wave
and ST elevation (Fig. 4A) and appeared in association with
syncope episodes [46], fever [47], administration of antiarrhyth-
mic drug [48], and glucose tolerance test [49]. Antiarrhythmic
drug-induced TWA was frequently observed in patients with
spontaneous VF [50]. Macroscopic TWA is associated with VF;
however, microvolt TWA induced by exercise did not predict the
occurrence of VF [51].
Although TWA occurred as a very short-term instability of
repolarization, patients also showed long-term ST-T variations
(Fig. 4B). The ST level is augmented especially in association with
VF episodes [52]. These ECG variations were termed ECG ﬂuctua-
tions [53] or alterations [41]. The ECG type in a patient can
alternate between types 1, 2, 3, and normal ECGs even if a typical
spontaneous type 1 ECG has been recorded. Patients who had
frequent appearances of type 1 ECG had more appropriate ICD
shocks [54] and VF induction by programmed stimulation [53].
ECG type alteration and ST level variations of Z0.20 mV were
independently associated with VF [41]. These indices of TWA and
ST alteration were evaluated in a small number of patients
(o1 0 0) and have not been tested in a randomized trial.
3.4. Abnormality in QT intervals
Some studies have analyzed abnormal QT intervals in patients
with Brugada syndrome, although they included small numbers
of patients. One study showed that a long QT interval in lead V2
(QTc 4460 ms) and a long Tpeak–Tend interval were associated
with VF events [55]. Moreover, the response of QT interval to RR
interval change is deteriorated in patients with VF [56]. Deep
negative T wave in lead V1 (o105 mV) is also associated with
poor prognosis during follow-up (odds ratio [OR], 8.98) [57].
These abnormalities in QT-T segments may represent abnormal
repolarization processes in the ventricle.
3.5. Physiologic provocation test to unmask type 1 ECG
The diagnostic type 1 ST-segment elevation is highly variable
over time and is often absent in affected individuals [41,53]. An
antiarrhythmic drug test with a sodium channel blocker is widely
used to unmask type 1 ECG. Some physiological provocation tests
for stratifying the risk of patients have been proposed.
V1
V2
V3
V4
V5
V6
Feb. 2008 Feb. 2009 Jun. 2010
Fig. 4. T-wave alterations. (A) T-wave alternans in a patient with ventricular ﬁbrillation. Arrows show the beat-by-beat changes of the negative T wave. (B) Spontaneous ST
alteration in an asymptomatic patient. This patient had type 2 or 3 ECGs, but type 1 ECG appeared spontaneously in February 2009.
V1
V2
V3
Responder to pilsicainide Non-responder to pilsicainide
V2
59°
15°
Control Pilsicainide Control Pilsicainide
Fig. 3. Response to pilsicainide in patients with non-type 1 ECG. Pilsicainide induced ST elevation in a patient with a large degree of late r0 wave (left). Patients with a sharp
degree of r0 wave did not respond to pilsicainide.
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stormy occurrence of VF events can be terminated by the admin-
istration of a b-adrenergic stimulant. However, some patients
have augmented ST elevation at the recovery phase of an exercise
test in which the vagal nerve activity may increase. Makimoto
et al. [58] reported that ST-segment augmentation at early
recovery during exercise testing was observed in a third of
patients and was an independent predictor for VF during
follow-up periods (HR, 3.17) (Fig. 5).
The ST level is augmented by the intake of glucose or a meal in
patients with Brugada syndrome [59–61]. A full stomach
test by intake of a large meal within 20 min at lunch augmented
ST elevation in high-risk patients with Brugada syndrome [62]
(OR, 7.1). The ST augmentation after meals will cause the
occurrence of ACA at night and after dinner during high vagal
nerve activity.3.6. Inferolateral early repolarization
Several studies have suggested an association of idiopathic VF
with ER or J wave [63]. Recently, inferolateral ER has been deﬁned
as an elevation of the J point (Z0.1 mV) in at least two leads and
includes QRS slurring or notching in inferior leads (II, III, and aVF),
lateral leads (I, aVL, and V4–V6), or both [5,63]. An ER pattern in
inferolateral leads is not rare in patients with Brugada syndrome
(Fig. 6), and its incidence was 11–12% [5,64,65]. This pattern of ST
elevation was not enhanced by an antiarrhythmic drug test [65,66]
but was frequently associated with VF or syncope episodes [5,65].
Kamakura et al. [5,65] demonstrated that inferolateral ER in
patients with spontaneous type 1 ECG was an independent
predictor of a fatal arrhythmic event (HR, 3.28), whereas Letsas
et al. [64] did not ﬁnd any signiﬁcant difference in the analysis of
ER in Brugada syndrome.
V1
56F VF
V2
V3
V4
V5
V6
I
II
III
aVR
aVL
aVF
II
III
V6
Fig. 6. Inferolateral early repolarization. This patient with spontaneous ventricular ﬁbrillation (VF) had type 1 ECG and inferolateral early repolarization (arrows).
Rest Post exercise 0 min Post exercise 3 min
V1
V2
V3
V4
V5
V6
ST level augmentation by exercise
Fig. 5. ST level augmentation by exercise. ST level increased and a typical type 1 ECG appeared after exercise.
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4.1. QRS interval and axis
It has been reported that a wide QRS complex is associated
with the occurrence of VF. Patients with VF often have a wide QRS
complex and S wave. An S wave width of Z80 ms in lead V1 has a
high sensitivity and speciﬁcity for patients with VF [36]. The
usefulness of a wide QRS complex for VF prediction was proved
by two studies that included a large number of patients. Takagiet al. [67] evaluated the QRS interval in the right precordial leads
as the ‘‘rJ interval,’’ and found that an rJ interval (V2) of Z90 ms
and a QRS interval (V6) of Z90 ms were possible predictors of the
recurrence of cardiac events in symptomatic patients. A subse-
quent study also showed that symptomatic patients had a wider
QRS complex (V2, 115726 ms) than did asymptomatic patients
(104719 ms), and that the optimized cutoff point of V2 QRS of
Z120 ms gave an OR of 2.5 for being symptomatic [68].
The axis of the QRS complex often becomes leftward in
direction in patients with Brugada syndrome. A study with a
T. Wada, H. Morita / Journal of Arrhythmia 29 (2013) 100–109106limited number of patients focused on lead aVR and deﬁned ‘‘aVR
sign’’ as R wave Z0.3 mV or R/q Z0.75 in lead aVR [69]. Patients
with aVR sign frequently had recurrent events during follow-up.
4.2. Fragmented QRS complex
Fragmented QRS (fQRS) is a convenient marker of ventricular
conduction disturbance. It is usually evaluated by analyzing
12-lead ECGs and is deﬁned as additional spikes within the QRS
complex [70]. We deﬁned the presence of fQRS in right bundle
branch block (RBBB) as 1) Z4 spikes in 1 or 2) Z8 spikes in all of
leads V1, V2, and V3 [71]. Only two control subjects with RBBB
(2.5%) were regarded as having fQRS by this criterion. Patients
with Brugada syndrome often had fQRS, and it was more fre-
quently observed in the VF group (incidence of fQRS: VF 85%,
syncope 50%, and asymptomatic 34%; po0.01) (Fig. 7). fQRS was
not associated with the late potential (LP) recorded by a signal-
averaged electrogram. Patients who had fQRS often experienced
recurrent VF within 4 years of the ﬁrst syncope or VF episodes.
Recently, the PRELUDE study has shown that fQRS was useful
for identifying candidates for prophylactic ICD implantation (HR,
4.9), in addition to spontaneous type 1 ECG and a history of
syncope as well as short ventricular refractory periods [4].
4.3. Prolongation of the PQ interval
Brugada et al. [1] in their initial report stated that patients
with ACA had a longer HV interval. The PQ interval was usually
normal, but patients with SCN5A mutation frequently had a
longer PQ interval than did patients without an SCN5A mutation
[72]. A recent study has shown that a long PQ interval (Z170 ms)
was an independent risk factor for life-threatening events (OR,
11.5) [57].
4.4. Signal-averaged electrogram
In patients with Brugada syndrome, LPs are frequently
detected by signal-averaged electrogram, especially in those with
syncope or VF (incidences of LPs: 57–73% in total patients, 89–
93% in patients with syncope, and 37–71% in asymptomatic
patients) [51,73–75] and represent conduction disturbance ofFragmented QRS
V1
V2
V3
V4
V5
V6
4th ICS 3rd ICS
Fig. 7. Fragmented QRS. This patient with ventricular ﬁbrillation (VF) had type 1 ECG a
multiple spikes within the QRS complex.the RVOT area [76]. Patients with LPs often had induced VF [73]
and showed daily ﬂuctuation of the LPs [75]. A study showed that
LPs are associated with subsequent cardiac events (HR, 10.9) [74].5. Other indices
5.1. Prediction of outcome by electrophysiological study
The value of the inducibility of sustained ventricular arrhyth-
mias during an electrophysiological study (EPS) for evaluating
arrhythmic risk in Brugada syndrome is controversial [9,10].
Brugada et al. [2,7] showed that the inducibility of ventricular
arrhythmias during an EPS was an independent predictor
for cardiac events (HR, 8.33). However, other studies and a
meta-analysis have failed to demonstrate its prognostic value
[3–5,11,14,71].
VF induction by a small number of extrastimuli might indicate
the existence of unstable arrhythmogenic substrate promoting
VF. A recent study showed that the number of extrastimuli that
induced VF served as a prognostic indicator for patients with type
1 ECG (HR, 3.21); however, the site of induction and the coupling
interval that induced VF were not associated with cardiac events
[77]. However, previous studies failed to show the prognostic
value of the number of extrastimuli [4,14,35], and a prospective
study with a large number of patients is required to prove the
signiﬁcance of the number of extrastimuli.
As parameters recorded during EPS, the signiﬁcance of HV
interval and ventricular refractory periods has been reported. The
HV interval was prolonged in symptomatic patients but did not
show a prognostic value [35]. Recently, a ventricular refractory
period o200 ms has been identiﬁed as an independent predictor
of ventricular arrhythmias (HR, 3.91) [4].
5.2. Atrial arrhythmias
It is well known that patients with Brugada syndrome often
have atrial arrhythmias, especially atrial ﬁbrillation (AF) [78]. AF
is an important cause of inappropriate discharge of an ICD in
patients with Brugada syndrome [79]. The occurrence of AF is
associated with cardiac events [79], and sometimes a new onset2nd ICS
4th ICS
3rd ICS
2nd ICS
Lead V2
nd fragmented QRS in leads located at high intercostal spaces (ICSs). Arrows show
Table 3
Proposed risk stratiﬁcation in Brugada syndrome.
Asymptomatic
patients
Step 1 Spontaneous type 1 ECG (at any intercostal
spaces)
Step 2 VF induction by single or double extrastimuli
ERP o200 ms
Step 3 Fragmented QRS
Inferolateral ER
Exercise-induced ST elevation
Patients with
syncope
Step 1 Type 1 ECG (spontaneous or drug-induced)
Step 2 Syncope without speciﬁc prodromes
Step 3 VF induction by single or double extrastimuli
ERPo200 ms
Step 4 Fragmented QRS
Inferolateral ER
Exercise-induced ST elevation
Additional
observations
Family history of sudden death (o45 years)
PQ prolongation (Z170 ms)
wide QRS complex (Z120 ms)
T-wave alternans
Spontaneous ST alteration (Z2 mm)
ST augmentation by meal or full stomach
Atrial ﬁbrillation, sick sinus syndrome
Late potential by SAECG
T. Wada, H. Morita / Journal of Arrhythmia 29 (2013) 100–109 107of AF precedes VF [80]. The occurrence of bradyarrhythmias is
associated with high-risk patients [81]; however, it is not known
whether AF and bradyarrhythmia can predict the development of
VF during follow-up.6. Summary and proposed risk stratiﬁcation
The risk stratiﬁcation of individuals without ACA is still
controversial. As we have reviewed, many indices have been
reported as prognostic predictors, but they are not always useful
for identifying high-risk patients who do not have documented
VF. In Japan, although most multicenter studies showed that
patients with type 1 ECG were at high risk, it is difﬁcult to
determine whether implantation of an ICD should be preferred on
the basis only of the ECG type.
The decision to implant an ICD in asymptomatic patients may
be made by VF induction with a single or double extrastimuli in
addition to the presence of spontaneous type 1 ECG [77]. The
indication for an EPS is determined by the existence of ECG
changes, including fQRS, inferolateral ER, and exercise-induced ST
augmentation. If patients have one of these ECG ﬁndings, an EPS is
recommended.
In patients with syncope episodes, detecting type 1 ECG
(spontaneous or drug-induced) and evaluating the characteristics
of symptoms are important for determining the indication for ICD
implantation. The result of EPS is supportive; however, it should
be noted that VF is not induced during EPS in all patients who
have spontaneous VF episodes and that syncope is an important
symptom preceding VF. The existence of fQRS, ER, and exercise-
induced ST augmentation should also be considered (Table 3).
To determine the risk for patients, indices including family
history and other various ECG markers are also considered in both
asymptomatic patients and in those with syncope.
The incidence of a new onset of VF is not high in asymptomatic
cases, and various clinical markers should be evaluated to identify
high-risk patients in the future.Conﬂict of interest
None.Acknowledgments
This work was supported by a Grant-in-Aid for Scientiﬁc
Research (C, 50322227) of Japan Society for the Promotion of
Science (JSPS) and a research grant for cardiovascular diseases
(H24-033) from the Ministry of Health, Labor, and Welfare of
Japan.References
[1] Brugada P, Brugada J. Right bundle branch block, persistent ST segment
elevation and sudden cardiac death: a distinct clinical and electrocardio-
graphic syndrome. A multicenter report. J Am Coll Cardiol 1992;20:1391–6.
[2] Brugada J, Brugada R, Antzelevitch C, et al. Long-term follow-up of
individuals with the electrocardiographic pattern of right bundle-branch
block and ST-segment elevation in precordial leads V1 to V3. Circulation
2002;105:73–8.
[3] Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients
diagnosed with Brugada syndrome: Results from the FINGER Brugada
syndrome registry. Circulation 2010;121:635–43.
[4] Priori SG, Gasparini M, Napolitano C, et al. Risk stratiﬁcation in Brugada
syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation
preDictive valuE) registry. J Am Coll Cardiol 2012;59:37–45.
[5] Kamakura S, Ohe T, Nakazawa K, et al. Long-term prognosis of probands with
Brugada-pattern ST-elevation in leads V1–V3. Circulat.: Arrhythmia Electro-
physiol 2009;2:495–503.
[6] Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment
elevation in leads V1 through V3: a marker for sudden death in patients
without demonstrable structural heart disease. Circulation 1998;97:457–60.
[7] Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in
individuals with the electrocardiographic pattern of Brugada syndrome and
no previous cardiac arrest. Circulation 2003;108:3092–6.
[8] Myerburg RJ, Marchlinski FE, Scheinman MM. Controversy on electrophysiol-
ogy testing in patients with Brugada syndrome. Heart Rhythm 2011;8:
1972–4.
[9] Brugada J, Brugada R, Brugada P. Electrophysiologic testing predicts events in
Brugada syndrome patients. Heart Rhythm 2011;8:1595–7.
[10] Wilde AA, Viskin S. EP testing does not predict cardiac events in Brugada
syndrome. Heart Rhythm 2011;8:1598–600.
[11] Gehi AK, Duong TD, Metz LD, et al. Risk stratiﬁcation of individuals with the
Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol
2006;17:577–83.
[12] Paul M, Gerss J, Schulze-Bahr E, et al. Role of programmed ventricular
stimulation in patients with Brugada syndrome: a meta-analysis of world-
wide published data. Eur Heart J 2007;28:2126–33.
[13] Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of
the second consensus conference: endorsed by the Heart Rhythm Society and
the European Heart Rhythm Association. Circulation 2005;111:659–70.
[14] Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada
syndrome: insights for risk stratiﬁcation and management. Circulation
2002;105:1342–7.
[15] Roos M, Sarkozy A, Brodbeck J, et al. The importance of class-I antiarrhyth-
mic drug test in the evaluation of patients with syncope: unmasking Brugada
syndrome. J Cardiovasc Electrophysiol 2012;23:290–5.
[16] Raju H, Papadakis M, Govindan M, et al. Low prevalence of risk markers in
cases of sudden death due to Brugada syndrome relevance to risk stratiﬁca-
tion in Brugada syndrome. J Am Coll Cardiol 2011;57:2340–5.
[17] Kubala M, Aissou L, Traulle S, et al. Use of implantable loop recorders in
patients with Brugada syndrome and suspected risk of ventricular arrhyth-
mia. Europace 2012;14:898–902.
[18] Yokokawa M, Okamura H, Noda T, et al. Neurally mediated syncope as a
cause of syncope in patients with Brugada electrocardiogram. J Cardiovasc
Electrophysiol 2010;21:186–92.
[19] Sacher F, Arsac F, Wilton SB, et al. Syncope in Brugada syndrome patients:
prevalence, characteristics, and outcome. Heart Rhythm 2012;9:1272–9.
[20] Take Y, Morita H, Toh N, et al. Identiﬁcation of high-risk syncope related to
ventricular ﬁbrillation in patients with Brugada syndrome. Heart Rhythm
2012;9:752–9.
[21] Sarkozy A, Sorgente A, Boussy T, et al. The value of a family history of sudden
death in patients with diagnostic type I Brugada ECG pattern. Eur Heart J
2011;32:2153–60.
[22] Brugada P, Brugada R, Brugada J. Sudden death in high-risk family members:
Brugada syndrome. Am J Cardiol 2000;86:40K–3K.
[23] Nishii N, Ogawa M, Morita H, et al. SCN5A mutation is associated with early
and frequent recurrence of ventricular ﬁbrillation in patients with Brugada
syndrome. Circ J 2010;74:2572–8.
[24] Meregalli PG, Tan HL, Probst V, et al. Type of SCN5A mutation determines
clinical severity and degree of conduction slowing in loss-of-function sodium
channelopathies. Heart Rhythm 2009;6:341–8.
[25] Antzelevitch C. Genetic, molecular and cellular mechanisms underlying the
J wave syndromes. Circ J 2012;76:1054–65.
T. Wada, H. Morita / Journal of Arrhythmia 29 (2013) 100–109108[26] Eckardt L. Gender differences in Brugada syndrome. J Cardiovasc Electro-
physiol 2007;18:422–4.
[27] Di Diego JM, Cordeiro JM, Goodrow RJ, et al. Ionic and cellular basis for the
predominance of the Brugada syndrome phenotype in males. Circulation
2002;106:2004–11.
[28] Matsuo K, Akahoshi M, Seto S, Yano K. Disappearance of the Brugada-type
electrocardiogram after surgical castration: a role for testosterone and an
explanation for the male preponderance. Pacing and Clin Electrophysiol
2003;26:1551–3.
[29] Shimizu W, Matsuo K, Kokubo Y, et al. Sex hormone and gender
difference—role of testosterone on male predominance in Brugada syn-
drome. J Cardiovasc Electrophysiol 2007;18:415–21.
[30] Benito B, Sarkozy A, Mont L, et al. Gender differences in clinical manifesta-
tions of Brugada syndrome. J Am Coll Cardiol 2008;52:1567–73.
[31] Brugada P, Benito B, Brugada R, et al. Brugada syndrome: update 2009.
Hellenic J Cardiol 2009;50:352–72.
[32] Oe H, Takagi M, Tanaka A, et al. Prevalence and clinical course of the
juveniles with Brugada-type ECG in Japanese population. Pacing Clin Electro-
physiol 2005;28:549–54.
[33] Yamakawa Y, Ishikawa T, Uchino K, et al. Prevalence of right bundle-branch
block and right precordial ST-segment elevation (Brugada-type electrocar-
diogram) in Japanese children. Circ J 2004;68:275–9.
[34] Probst V, Denjoy I, Meregalli PG, et al. Clinical aspects and prognosis of
Brugada syndrome in children. Circulation 2007;115:2042–8.
[35] Brugada P, Brugada R, Mont L, et al. Natural history of Brugada syndrome:
the prognostic value of programmed electrical stimulation of the heart.
J Cardiovasc Electrophysiol 2003;14:455–7.
[36] Atarashi H, Ogawa S. New ECG criteria for high-risk Brugada syndrome. Circ J
2003;67:8–10.
[37] Hisamatsu K, Morita H, Fukushima Kusano K, et al. Evaluation of the
usefulness of recording the ECG in the 3rd intercostal space and prevalence
of Brugada-type ECG in accordance with recently established electrocardio-
graphic criteria. Circ J 2004;68:135–8.
[38] Shimizu W, Matsuo K, Takagi M, et al. Body surface distribution and
response to drugs of ST segment elevation in Brugada syndrome: clinical
implication of eighty-seven-lead body surface potential mapping and its
application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol
2000;11:396–404.
[39] Miyamoto K, Yokokawa M, Tanaka K, et al. Diagnostic and prognostic value
of a type 1 Brugada electrocardiogram at higher (third or second) V1 to V2
recording in men with Brugada syndrome. Am J Cardiol 2007;99:53–7.
[40] Nagase S, Hiramatsu S, Morita H, et al. Electroanatomical correlation of
repolarization abnormalities in Brugada syndrome: detection of type 1 elec-
trocardiogram in the right ventricular outﬂow tract. J Am Coll Cardiol
2010;56:2143–5.
[41] Take Y, Morita H, Wu J, et al. Spontaneous electrocardiogram alterations
predict ventricular ﬁbrillation in Brugada syndrome. Heart Rhythm 2011;8:
1014–21.
[42] Morita H, Zipes DP, Wu J. Brugada syndrome: insights of ST elevation,
arrhythmogenicity, and risk stratiﬁcation from experimental observations.
Heart Rhythm 2009;6:S34–43.
[43] Evain S, Briec F, Kyndt F, et al. Sodium channel blocker tests allow a clear
distinction of electrophysiological characteristics and prognosis in patients
with a type 2 or 3 Brugada electrocardiogram pattern. Heart Rhythm 2008;5:
1561–4.
[44] Chevallier S, Forclaz A, Tenkorang J, et al. New electrocardiographic criteria
for discriminating between Brugada types 2 and 3 patterns and incomplete
right bundle branch block. J Am Coll Cardiol 2011;58:2290–8.
[45] Morita H, Zipes DP, Lopshire J, et al. T wave alternans in an in vitro canine
tissue model of Brugada syndrome. Am J Physiol: Heart Circ Physiol
2006;291:H421–8.
[46] Schulze-Bahr E, Zoelch KA, Eckardt L, et al. Electrical alternans in long QT
syndrome resembling a Brugada syndrome pattern. Pacing Clin Electrophy-
siol 2003;26:2033–5.
[47] Morita H, Nagase S, Kusano K, et al. T. Spontaneous T wave alternans and
premature ventricular contractions during febrile illness in a patient with
Brugada syndrome. J Cardiovasc Electrophysiol 2002;13:816–8.
[48] Tada H, Nogami A, Shimizu W, et al. ST segment and T wave alternans
in a patient with Brugada syndrome. Pacing Clin Electrophysiol
2000;23:413–5.
[49] Nishizaki M, Fujii H, Sakurada H, et al. Spontaneous T wave alternans in a
patient with Brugada syndrome—responses to intravenous administration
of class I antiarrhythmic drug, glucose tolerance test, and atrial pacing.
J Cardiovasc Electrophysiol 2005;16:217–20.
[50] Morita H, Morita ST, Nagase S, et al. Ventricular arrhythmia induced by
sodium channel blocker in patients with Brugada syndrome. J Am Coll
Cardiol 2003;42:1624–31.
[51] Ikeda T, Sakurada H, Sakabe K, et al. Assessment of noninvasive markers in
identifying patients at risk in the Brugada syndrome: insight into risk
stratiﬁcation. J Am Coll Cardiol 2001;37:1628–34.
[52] Matsuo K, Shimizu W, Kurita T, et al. Dynamic changes of 12-lead
electrocardiograms in a patient with Brugada syndrome. J Cardiovasc
Electrophysiol 1998;9:508–12.
[53] Veltmann C, Schimpf R, Echternach C, et al. A prospective study on
spontaneous ﬂuctuations between diagnostic and non-diagnostic ECGs inBrugada syndrome: implications for correct phenotyping and risk stratiﬁca-
tion. Eur Heart J 2006;27:2544–52.
[54] Richter S, Sarkozy A, Veltmann C, et al. Variability of the diagnostic ECG
pattern in an ICD patient population with Brugada syndrome. J Cardiovasc
Electrophysiol 2009;20:69–75.
[55] Castro Hevia J, Antzelevitch C, Tornes Barzaga F, et al. Tpeak–Tend and
Tpeak–Tend dispersion as risk factors for ventricular tachycardia/ventricular
ﬁbrillation in patients with the Brugada syndrome. J Am Coll Cardiol
2006;47:1828–34.
[56] Sangawa M, Morita H, Nakatsu T, et al. Abnormal transmural repolarization
process in patients with Brugada syndrome. Heart Rhythm 2009;6:1163–9.
[57] Miyamoto A, Hayashi H, Makiyama T, et al. Risk determinants in individuals
with a spontaneous type 1 Brugada ECG. Circ J 2011;75:844–51.
[58] Makimoto H, Nakagawa E, Takaki H, et al. Augmented ST-segment elevation
during recovery from exercise predicts cardiac events in patients with
Brugada syndrome. J Am Coll Cardiol 2010;56:1576–84.
[59] Nishizaki M, Sakurada H, Ashikaga T, et al. Effects of glucose-induced insulin
secretion on ST segment elevation in the Brugada syndrome. J Cardiovasc
Electrophysiol 2003;14:243–9.
[60] Nishizaki M, Sakurada H, Mizusawa Y, et al. Inﬂuence of meals on variations
of ST segment elevation in patients with Brugada syndrome. J Cardiovasc
Electrophysiol 2008;19:62–8.
[61] Nogami A, Nakao M, Kubota S, et al. Enhancement of J-ST-segment elevation
by the glucose and insulin test in Brugada syndrome. Pacing Clin Electro-
physiol 2003;26:332–7.
[62] Ikeda T, Abe A, Yusu S, et al. The full stomach test as a novel diagnostic
technique for identifying patients at risk of Brugada syndrome. J Cardiovasc
Electrophysiol 2006;17:602–7.
[63] Haissaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated
with early repolarization. N Eng J Med 2008;358:2016–23.
[64] Letsas KP, Sacher F, Probst V, et al. Prevalence of early repolarization pattern
in inferolateral leads in patients with Brugada syndrome. Heart Rhythm
2008;5:1685–9.
[65] Sarkozy A, Chierchia GB, Paparella G, et al. Inferior and lateral electrocardio-
graphic repolarization abnormalities in Brugada syndrome. Circulat:
Arrhythmia Electrophysiol 2009;2:154–61.
[66] Kawata H, Noda T, Yamada Y, et al. Effect of sodium-channel blockade on
early repolarization in inferior/lateral leads in patients with idiopathic
ventricular ﬁbrillation and Brugada syndrome. Heart Rhythm 2012;9:77–83.
[67] Takagi M, Yokoyama Y, Aonuma K, et al. Clinical characteristics and risk
stratiﬁcation in symptomatic and asymptomatic patients with Brugada
syndrome: multicenter study in Japan. J Cardiovasc Electrophysiol 2007;18:
1244–51.
[68] Junttila MJ, Brugada P, Hong K, et al. Differences in 12-lead electrocardio-
gram between symptomatic and asymptomatic Brugada syndrome patients.
J Cardiovasc Electrophysiol 2008;19:380–3.
[69] Babai Bigi MA, Aslani A, Shahrzad S. aVR sign as a risk factor for life-
threatening arrhythmic events in patients with Brugada syndrome. Heart
Rhythm 2007;4:1009–12.
[70] Das MK, Saha C, El Masry H, et al. Fragmented QRS on a 12-lead ECG: a
predictor of mortality and cardiac events in patients with coronary artery
disease. Heart Rhythm 2007;4:1385–92.
[71] Morita H, Kusano KF, Miura D, et al. Fragmented QRS as a marker of
conduction abnormality and a predictor of prognosis of Brugada syndrome.
Circulation 2008;118:1697–704.
[72] Yokokawa M, Noda T, Okamura H, et al. Comparison of long-term follow-up
of electrocardiographic features in Brugada syndrome between the SCN5A-
positive probands and the SCN5A-negative probands. Am J Cardiol
2007;100:649–55.
[73] Morita H, Takenaka-Morita S, Fukushima-Kusano K, et al. Risk stratiﬁca-
tion for asymptomatic patients with Brugada syndrome. Circ J 2003;67:
312–6.
[74] Huang Z, Patel C, Li W, et al. Role of signal-averaged electrocardiograms in
arrhythmic risk stratiﬁcation of patients with Brugada syndrome: a prospec-
tive study. Heart Rhythm 2009;6:1156–62.
[75] Tatsumi H, Takagi M, Nakagawa E, et al. Risk stratiﬁcation in patients with
Brugada syndrome: analysis of daily ﬂuctuations in 12-lead electrocardio-
gram (ECG) and signal-averaged electrocardiogram (SAECG). J Cardiovasc
Electrophysiol 2006;17:705–11.
[76] Hisamatsu K, Kusano KF, Morita H, et al. Relationships between depolariza-
tion abnormality and repolarization abnormality in patients with Brugada
syndrome: using body surface signal-averaged electrocardiography and body
surface maps. J Cardiovasc Electrophysiol 2004;15:870–6.
[77] Makimoto H, Kamakura S, Aihara N, et al. Clinical impact of the number of
extrastimuli in programmed electrical stimulation in patients with Brugada
type 1 electrocardiogram. Heart Rhythm 2012;9:242–8.
[78] Morita H, Kusano-Fukushima K, Nagase S, et al. Atrial ﬁbrillation and atrial
vulnerability in patients with Brugada syndrome. J Am Coll Cardiol
2002;40:1437–44.
[79] Bordachar P, Reuter S, Garrigue S, et al. Incidence, clinical implications and
prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J 2004;25:
879–84.
[80] Pappone C, Radinovic A, Manguso F, et al. New-onset atrial ﬁbrillation as ﬁrst
clinical manifestation of latent Brugada syndrome: prevalence and clinical
signiﬁcance. Eur Heart J 2009;30:2985–92.
T. Wada, H. Morita / Journal of Arrhythmia 29 (2013) 100–109 109[81] Makiyama T, Akao M, Tsuji K, et al. High risk for bradyarrhythmic
complications in patients with Brugada syndrome caused by SCN5A gene
mutations. J Am Coll Cardiol 2005;46:2100–6.
[82] Priori SG, Napolitano C, Gasparini M, et al. Clinical and genetic heterogeneity
of right bundle branch block and ST-segment elevation syndrome: A
prospective evaluation of 52 families. Circulation 2000;102:2509–2515.
[83] Atarashi H, Ogawa S, Harumi K, et al. Three-year follow-up of patients with
right bundle branch block and ST segment elevation in the right precordial
leads: Japanese Registry of Brugada Syndrome. Idiopathic VentricularFibrillation Investigators. Journal of the American College of Cardiology
2001;37:1916–1920.
[84] Brugada P, Brugada R, Mont L, Rivero M, Geelen P, Brugada J. Natural history
of Brugada syndrome: the prognostic value of programmed electrical
stimulation of the heart. Journal of cardiovascular electrophysiology
2003;14:455–457.
[85] Eckardt L, Probst V, Smits JP, et al. Long-term prognosis of individuals with
right precordial ST-segment-elevation Brugada syndrome. Circulation
2005;111:257–263.
